McKesson Corporation: Strong Q3 Earnings But Upside Exhausted

McKesson Corporation shares are now fairly valued after a 16% price increase, prompting a Hold rating. Strong Q3 results were driven by 11% revenue growth and a 37% surge in the Oncology & Multispeciality segment, aided by M&A. Management raised FY2026 guidance, with EPS now expected at $38.80–39.20 and revenue growth at 12–16%.

Seeking Alpha • 12 hours ago

Wall Street Analysts Think McKesson (MCK) Is a Good Investment: Is It?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Zacks Investment Research • 12 hours ago

Investors Heavily Search McKesson Corporation (MCK): Here is What You Need to Know

McKesson (MCK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks Investment Research • Feb 23, 2026

Allspring Large Cap Growth Fund Q4 2025 Performance Update

The Allspring Large Cap Growth Fund underperformed the Russell 1000 Growth Index during the fourth quarter. As VYVGART gains traction with new patients, argenx continues to advance its pipeline, targeting additional autoimmune disorders to further broaden its impact. With a record backlog and a global footprint, we believe that Johnson Controls is well positioned to capitalize on demand for energy-efficient solutions, digital building automation, and data center investments.

Seeking Alpha • Feb 19, 2026

McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know

McKesson (MCK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks Investment Research • Feb 10, 2026

How McKesson Stock Surged 17% In A Day

McKesson (MCK), a prominent pharmaceutical wholesaler, experienced a stock increase of 17% during a high-volume trading session. The driver for this surge was a strong Q3 earnings report that surpassed expectations and, more importantly, a significant rise in the full-year 2026 adjusted EPS forecast.

Forbes • Feb 6, 2026

MCK Q3 Earnings & Sales Top Estimates, 2026 View Up

McKesson beats Q3 EPS and revenue estimates, raises fiscal 2026 guidance, and delivers broad-based growth led by oncology, specialty distribution and technology.

Zacks Investment Research • Feb 6, 2026

Why McKesson (MCK) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Feb 6, 2026

McKesson (MCK) Is Considered a Good Investment by Brokers: Is That True?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Zacks Investment Research • Feb 5, 2026

Trump Ally Mullin Buys 10 Stocks, Including These $5 Billion Companies You've Probably Never Heard Of

Mullin reported the purchase of 10 stocks in a new disclosure, according to the Benzinga Government Trades page. The stock purchases were all made on Jan. 5, 2026, with Mullin reporting two purchases of $15,000 to $50,000 of each of the 10 stocks.

Benzinga • Feb 6, 2026